# An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

> **NCT06321055** · — · COMPLETED · sponsor: **Bayer** · enrollment: 136 (actual)

## Conditions studied

- Advanced Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)

## Key facts

- **NCT ID:** NCT06321055
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06321055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06321055, "An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06321055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*